CoChat

Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis

Open access
Angus, B. J., Smith, M. D., Suputtamongkol, Y., Mattie, H., Walsh, A. L., Wuthiekanun, V., Chaowagul, W., White, N. J. · 2000 · British Journal of Clinical Pharmacology
Cited by 114

The DOI matches its Crossref record.

Abstract

Aims Experimental studies have suggested that constant intravenous infusion would be preferable to conventional intermittent bolus administration of beta‐lactam antibiotics for serious Gram‐negative infections. Severe melioidosis (Burkholderia pseudomallei infection) carries a mortality over 40% despite treatment with high dose ceftazidime. The aim of this study was to measure the pharmacokinetic and pharmacodynamic effects of continuous infusion of ceftazidime vs intermittent bolus dosing in septicaemic melioidosis. Methods Patients with suspected septicaemic melioidosis were randomised to receive ceftazidime 40 mg kg−1 8 hourly by bolus injection or 4 mg kg−1 h−1 by constant infusion following a 12 mg kg−1 priming dose and pharmacokinetic and pharmacodynamic parameters were compared. Results Of the 34 patients studied 16 (59%) died. Twenty patients had cultures positive for B. pseudomallei of whom 12 (60%) died. The median MIC 90 of B. pseudomallei was 2 mg l−1, giving a minimum target concentration (4*MIC) of 8 mg l−1. The median (range) estimated total apparent volume of distribution, systemic clearance and terminal elimination half‐lives of ceftazidime were 0.468 (0.241–0.573) l kg−1, 0.058 (0.005–0.159) l kg−1 h−1 and 7.74 (1.95–44.71) h, respectively. Clearance of ceftazidime and creatinine clearance were correlated closely (r = 0.71; P < 0.001) and there was no evidence of significant nonrenal clearance. Conclusions Simulations based on these data and the ceftazidime sensitivity of the B. pseudomallei isolates indicated that administration by constant infusion would allow significant dose reduction and cost saving. With conventional 8 h intermittent dosing to patients with normal renal function, plasma ceftazidime concentrations could fall below the target concentration but this would be unlikely with a constant infusion. Correction for renal failure, which is common in patients with meliodosis is Clearance =k* creatinine clearance where k = 0.72. Calculation of a loading dose gives median (range) values of loading dose, DL of 18.7 mg kg−1 (9.5–23) and infusion rate I = 3.5 mg kg−1 h−1 (0.4–13) (which equals 84 mg kg−1 day−1). A nomogram for adjustment in renal failure is given.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2000.00179.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 43

  1. 10.1093/jac/24.3.281 · doi:10.1093/jac/24.3.281
  2. 10.1128/AAC.35.3.399 · DOI · Paper page
  3. 10.1093/infdis/158.4.831 · DOI · Paper page
  4. 10.1128/AAC.32.3.289 · DOI · Paper page
  5. 10.1159/000138851 · doi:10.1159/000138851
  6. 10.1128/AAC.38.5.931 · DOI · Paper page
  7. 10.1093/jac/43.2.309 · DOI
  8. 10.1086/514622 · DOI · Paper page
  9. 10.1177/106002809502900413 · doi:10.1177/106002809502900413
  10. 10.1093/infdis/159.5.890 · DOI · Paper page
  11. 10.1016/S0140-6736(89)90768-X · DOI
  12. 10.1093/clinids/19.5.846 · doi:10.1093/clinids/19.5.846
  13. 10.1093/jac/24.3.295 · DOI
  14. 10.1093/jac/33.1.145 · doi:10.1093/jac/33.1.145
  15. 10.1093/clinids/21.6.1498 · DOI
  16. 10.1099/00222615-33-2-121 · doi:10.1099/00222615-33-2-121
  17. 10.1136/jcp.42.6.645 · doi:10.1136/jcp.42.6.645
  18. 10.1016/0035-9203(95)90104-3 · doi:10.1016/0035-9203(95)90104-3
  19. 10.1007/BF00542421 · doi:10.1007/bf00542421
  20. 10.1128/AAC.24.3.343 · doi:10.1128/aac.24.3.343
  21. 10.1159/000180580 · DOI · Paper page
  22. 10.1111/j.1365-2125.1989.tb05427.x · doi:10.1111/j.1365-2125.1989.tb05427.x
  23. 10.1093/ije/23.5.1082 · DOI · Paper page
  24. 10.2165/00003495-198529020-00002 · doi:10.2165/00003495-198529020-00002
  25. 10.1128/AAC.23.6.892 · doi:10.1128/aac.23.6.892
  26. 10.3109/00365548909035704 · doi:10.3109/00365548909035704
  27. 10.1128/AAC.25.5.638 · doi:10.1128/aac.25.5.638
  28. 10.1002/j.1552-4604.1989.tb03337.x · doi:10.1002/j.1552-4604.1989.tb03337.x
  29. 10.1093/jac/40.1.125 · DOI
  30. Ganzinger U, 1987, Pharmacokinetics of ceftazidime and netilimicin in patients with sepsis, Int J Pharmacol Ther Toxicol, 25, 354
  31. Rondanelli R, 1986, Ceftazidime in the treatment of Pseudomonas infections in intensive‐care patients, Int J Clin Pharmacol Ther Toxicol, 24, 457
  32. 10.1007/BF01709707 · doi:10.1007/bf01709707
  33. 10.1128/AAC.37.3.464 · doi:10.1128/aac.37.3.464
  34. 10.1016/S0140-6736(86)92106-9 · doi:10.1016/s0140-6736(86)92106-9
  35. 10.1093/jac/28.1.95 · doi:10.1093/jac/28.1.95
  36. 10.1093/jac/15.3.365 · doi:10.1093/jac/15.3.365
  37. 10.1016/0195-6701(90)90076-Z · doi:10.1016/0195-6701(90)90076-z
  38. 10.1128/AAC.32.3.298 · DOI
  39. 10.1093/jac/40.2.269 · DOI
  40. Benko AS, 1996, Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram‐negative infections, Antimicrob Agents Chemother, 40, 691, 10.1128/AAC.40.3.691 · DOI · Paper page
  41. 10.1128/AAC.41.9.2053 · DOI
  42. 10.1002/j.1875-9114.1985.tb03424.x · DOI
  43. Couldry R, 1998, Continuous infusion of ceftazidime with an elastomeric infusion device, Am J Health Syst Pharm, 55, 145, 10.1093/ajhp/55.2.145 · doi:10.1093/ajhp/55.2.145

Cited by

See all 114

Metadata

Authors
Angus, B. J., Smith, M. D., Suputtamongkol, Y., Mattie, H., Walsh, A. L., Wuthiekanun, V., Chaowagul, W., & White, N. J.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2000-08
Volume
50
Issue
2
Pages
184-191
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2057650704
Cited by
114
References
0
FWCI
2.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. https://app.cochat.ai/papers/10.1111/j.1365-2125.2000.00179.x
The paper
Angus, B. J., Smith, M. D., Suputtamongkol, Y., Mattie, H., Walsh, A. L., Wuthiekanun, V., Chaowagul, W., & White, N. J. (2000). Pharmacokinetic‐pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2000.00179.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.